Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion - 1 Jan 2000

Ruiz-Argüelles Guillermo J, Garcés-Eisele Javier, Reyes-Núñez Virginia, Ruiz-Delgado Guillermo J, Navarro-Vázquez Morelis, González-Carrillo Martha L

Abstract excerpt

A new mutation (V617F) affecting the JAK2 gene has been recently described as acquired in patients with myeloproliferative disorders and other myeloid malignancies. Using an amplification refractory mutation system, we investigated this mutation in 70 Mexican mestizo patients with hematological malignancies: 28 cases of acute lymphoblastic leukemia, 17 cases of Ph1-positive chronic myelogenous leukemia, 8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BCR gene
Share to JAK2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Janus Kinase 2

Share to Mexico

Share to Mutation

Source

Identifiers

PMID: 17408106

Genes

JAK2
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.PMID 17408106Read ↗

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.Semantic proximity Read ↗

Molecular characterization of chronic myeloproliferative neoplasias in México.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Semantic proximity Read ↗

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasmsSemantic proximity Read ↗

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.Semantic proximity Read ↗

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.Semantic proximity Read ↗

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.Semantic proximity Read ↗

Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.Semantic proximity Read ↗

Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.Semantic proximity Read ↗

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.Semantic proximity Read ↗

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.